Abstract
Genome-wide association studies have revealed many breast cancer (BC) risk-associated genetic variants that might functionally interact with other molecular determinants of BC. We analysed the association of 21 known risk-associated single-nucleotide variants (SNVs) with recurrent somatic variants in two cohorts of 77 and 754 oestrogen receptor α-positive BCs. Four SNVs located at 5q11.2 were found to be associated with the somatic PIK3CA variant status in the pilot cohort of 77 cases with odds ratio (OR) up to 6.5 indicating strong effects, and were selected for the validation phase. Two of these SNVs, rs252913 and rs331499, located in the MAP3K1/SETD9 gene boundary, were confirmed to be associated with somatic PIK3CA variants in the large cohort with OR 2.97 (1.17–7.75) and 1.76 (1.11–2.77), respectively, notably higher than their BC risk-associated values, both around 1.1. In the presence of the SNV or of somatic PIK3CA variants, cancers express significantly elevated levels of MAP3K1 and SETD9, with synergy of SNV and PIK3CA variants in MAP3K1 gene overexpression, consistent with a preferential PIK3CA-dependent regulation of the variant alleles.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Foulkes WD : Inherited susceptibility to common cancers. N Engl J Med 2008; 359: 2143–2153.
Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA : Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002; 31: 33–36.
Mucci LA, Hjelmborg JB, Harris JR et al: Familial risk and heritability of cancer among twins in Nordic countries. JAMA 2016; 315: 68–76.
Michailidou K, Beesley J, Lindstrom S et al: Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet 2015; 47: 373–380.
Harlid S, Ivarsson MI, Butt S et al: Combined effect of low-penetrant SNVs on breast cancer risk. Br J Cancer 2012; 106: 389–396.
Stephens PJ, Tarpey PS, Davies H et al: The landscape of cancer genes and mutational processes in breast cancer. Nature 2012; 486: 400–404.
Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61–70.
Stratton MR, Campbell PJ, Futreal PA : The cancer genome. Nature 2009; 458: 719–724.
O'Brien KM, Cole SR, Engel LS et al: Breast cancer subtypes and previously established genetic risk factors: a bayesian approach. Cancer Epidemiol Biomarkers Prev 2014; 23: 84–97.
Li Q, Seo JH, Stranger B et al: Integrative eQTL-based analyses reveal the biology of breast cancer risk loci. Cell 2013; 152: 633–641.
Lu PH, Yang J, Li C et al: Association between mitogen-activated protein kinase kinase kinase 1 rs889312 polymorphism and breast cancer risk: evidence from 59977 subjects. Breast Cancer Res Treat 2011; 126: 663–670.
Rhie SK, Coetzee SG, Noushmehr H et al: Comprehensive functional annotation of seventy-one breast cancer risk Loci. PLoS One 2013; 8: e63925.
Ellis MJ, Ding L, Shen D et al: Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012; 486: 353–360.
Tryka KA, Hao L, Sturcke A et al: NCBI's Database of Genotypes and Phenotypes: dbGaP. Nucleic Acids Res 2014; 42: D975–D979.
Wilks C, Cline MS, Weiler E et al: The Cancer Genomics Hub (CGHub): overcoming cancer through the power of torrential data. Database 2014, e-pub ahead of print 29 September 2014 doi:10.1093/database/bau093.
Cerami, Gao J, Dogrusoz U et al: The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401.
Nyholt DR : A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004; 74: 765–769.
Glubb DM, Maranian MJ, Michailidou K et al: Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. Am J Hum Genet 2015; 96: 5–20.
Aksamitiene E, Kiyatkin A, Kholodenko BN : Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochem Soc Trans 2012; 40: 139–146.
Britten CD : PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. Cancer Chemother Pharmacol 2013; 71: 1395–1409.
Lu Z, Xu S, Joazeiro C, Cobb MH, Hunter T : The PHD domain of MEKK1 acts as an E3 ubiquitin ligase and mediates ubiquitination and degradation of ERK1/2. Mol Cell 2002; 9: 945–956.
Xia Y, Wang J, Xu S, Johnson GL, Hunter T, Lu Z : MEKK1 mediates the ubiquitination and degradation of c-Jun in response to osmotic stress. Mol Cell Biol 2007; 27: 510–517.
Acknowledgements
The results shown here are in part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/. We thank Paola Ghiorzo, Genova, for helpful comments.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on European Journal of Human Genetics website
Supplementary information
Rights and permissions
About this article
Cite this article
Puzone, R., Pfeffer, U. SNP variants at the MAP3K1/SETD9 locus 5q11.2 associate with somatic PIK3CA variants in breast cancers. Eur J Hum Genet 25, 384–387 (2017). https://doi.org/10.1038/ejhg.2016.179
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/ejhg.2016.179
This article is cited by
-
Association between germline variants and somatic mutations in colorectal cancer
Scientific Reports (2022)
